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Dear Editor, According to the data from the Edinburgh Type 2 Diabetes Study up to 43% of type 2 diabetes mellitus (T2DM) patients have non-alcoholic fatty liver disease (NAFLD) which is associated with greater burden of diabetic complications in T2DM population (1) . Liver biopsy, the gold standard for NAFLD diagnosis is not routinely performed because it is an invasive procedure with a certain degree of sampling error (2) . Instead, alternative diagnostic methods have been developed and fatty liver index (FLI) as a measure of liver fat content that correlates with abdominal ultrasound and is calculated using an equation including body mass index (BMI), waist circumference, triglycerides (TG) and GGT is one of them (3) . Glucagon-like peptide-1 (GLP-1) receptor agonist exenatide is a glucose lowering agent who possesses proven efficacy in achieving and maintaining glycaemic control, weight loss, and improvement in metabolic parameters (4) . The decrease in glycated haemoglobin (HbA1c) levels in T2DM patients treated with exenatide was shown to correlate with hepatic fat reduction (5) . Recent studies reported the presence of GLP-1 receptor on human hepatocytes and the possible direct exenatide modulation of intrahepatic lipid metabolism and insulin signalling with a consequent improvement in hepatic steatosis (6) .
The aim of our study was to evaluate the effect of exenatide therapy, alone or in combination with oral hypoglycaemic agents (OHA), compared to OHA on hepatic fat quantity measured by FLI.
Out of 125 T2DM patients included in the study, 61 (48.8%) were male, mean age was 57±8 years, BMI 38.57±5.35 kg/m2, waist circumference 119.5±14.5 cm, diabetes duration 12±7 years, and HbA1c level 8.57±1.49%. Eighty-seven recieved exenatide therapy: exenatide alone 17 (19.5%), exenatide and metformin 38 (43.7%), exenatide and sulphonylurea 7 (8%), exenatide and metformin and sulphonylurea 25 (28.7%), and 38 metformin or/and sulphonylurea, i.e. metformin 15 (39.5 %), sulphonylurea 2 (5.3%), metformin + sulphonylurea 21 (55.3%) patients. Exenatide was used in dosage of 10 µg twice daily. All subjects were studied in the morning between 08:00 and 09:30 hours after an overnight fast at the study entry and after 6 months. Basic anthropometric measurements were performed on all study subjects. Fasting venous blood samples were collected for the determination of Glucose, cholesterol and triglycerides in serum were measured by an enzymatic colorimetric method.
Complete blood count was determined on an automatic blood counter (Advia 120, Siemens Diagnostic Solutions, USA). Aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltransferase (GGT) and alkaline phosphatase (ALK) were measured using standard laboratory methods.
The detailed baseline and 6 months after characteristics as well as their changes are given in table 1.
The exenatide treated group showed significantly higher change in BMI, waist circumference, ALK, ALT and FLI while lower HbA1c change after 6 months treatment compared to OHA group.
In this open label parallel-group uncontrolled 6 months study we assessed changes in NAFLD markers, FLI, BMI, waist circumference, HbA1c and TG levels in two T2DM groups of patients, one treated with exenatide and the other treated with metformin or/and sulphonylurea. The data from our study suggests that the addition of exenatide to current OHA therapy results in reduction of NAFLD marker levels and intrahepatic fat quantity calculated by FLI. In both exenatide and OHA group a decrease in BMI and HbA1c value was noticed. Similar effect of GLP-1 agonists (exenatide and The reduction in hepatic fat content in exenatide group could be partially explained by reduced caloric intake which is one of the main therapeutic contributions of this drug (4) . That is in concordance with decrease in TG levels in the exenatide group and the increase of TG levels in the OHA group. That is also consistent with the BMI and waist circumference reduction which was greater in the exenatide group. However, patient food intake was not controlled, and both groups did have decrease in BMI as well as waist circumference so the effect of reduced caloric intake could be argued.
There are several studies explaining the molecular pleiotropic effect of exenatide on human The present study is limited by the unavailability of performing liver biopsy, the "gold standard" procedure for diagnosis of NAFLD.
In conclusion, introduction of exenatide therapy to T2DM patients seems to have positive pleiotropic effect in liver, especially in hepatic fat metabolism, although so far it has been mostly studied for its effect in weight reduction, glucose dependent insulin secretion with consequent glucoregulation and positive cardiovascular effects. However, whether the detection of decrease in hepatic fat content in T2DM patients treated with exenatide is due to GLP-1 based therapy itself or the ∆FLI is mostly due to improvement in abdominal fat accumulation needs to be assessed in further follow-up studies. 
